No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Dezhan Healthcare (000813.SZ) has signed a global strategy cooperation framework agreement with Baoshihua Medical.
Dezhan Healthcare (000813.SZ) announced that recently, it is leveraging the "Medical Special Zone" policy of Hainan Free Trade Port to accelerate the production...
Dezhan Healthcare (000813.SZ): The company is currently not involved in the Retirement robot Business.
On March 7, Gelonghui reported that Dezhan Healthcare (000813.SZ) stated on the investor interaction platform that the company is currently not involved in the Retirement Siasun Robot&Automation business.
Dezhan Healthcare (000813.SZ) has repurchased 1.32% of its shares, costing approximately 73.2659 million yuan.
Dezhan Healthcare (000813.SZ) issued an announcement that by February 28, 2025, the company will achieve share repurchase...
Dezhan Healthcare's Unit Applies for Development of Cannabidiol Suspension Granules
Dezhan Healthcare (000813.SZ): The cannabidiol suspension granules of Deyi Pharmaceutical have received an acceptance notice.
On February 27, Gelonghui reported that Dezhan Healthcare (000813.SZ) announced that on February 26, 2025, its subsidiary, Deyi Pharmaceutical Co., Ltd. (referred to as "Deyi Pharmaceutical"), received the "Acceptance Notification" from the National Medical Products Administration for the research and development project application of a Cannabidiol suspension granule for the treatment of rare disease pulmonary arterial hypertension. Cannabidiol (CBD), a cannabinoid naturally found in Industrial Cannabis, is widely used internationally in Pharmaceutical, Cosmetic, food, and manufacturing industries.
Further Weakness as Dezhan Healthcare (SZSE:000813) Drops 6.1% This Week, Taking Five-year Losses to 63%
